UCB has patented a method for treating autoimmune diseases like systemic lupus erythematosus using a specific antibody to CD154. The method involves administering specific doses of the antibody to human subjects with the disease. GlobalData’s report on UCB gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights UCB SA - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on UCB, Human telomerase RT biomarker was a key innovation area identified from patents. UCB's grant share as of January 2024 was 47%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of systemic lupus erythematosus with anti-cd154 antibody

Source: United States Patent and Trademark Office (USPTO). Credit: UCB SA

A recently granted patent (Publication Number: US11884737B2) discloses a method for treating systemic lupus erythematosus (SLE) using a specific monovalent antibody fragment binding to CD154. The method involves administering an initial loading dose of about 30 mg/kg of the antibody fragment to a human subject with SLE, followed by further doses of about 15 mg/kg every other week for at least 12 weeks. The antibody fragment used in the treatment contains specific amino acid sequences and structural modifications to enhance its efficacy in treating SLE.

Furthermore, the patent claims that the administration of the monovalent antibody fragment results in significant improvements in various indices such as SLEDAI, BILAG, and Global Physician assessment. The method aims to achieve specific outcomes such as SLEDAI Responder Index 4 (SRI-4), a 50% improvement from baseline in the SRI-50 index, normalization of complement C3 and C4 concentration, reduction in anti-double stranded DNA titre in serum, and even a reversion from seropositive to seronegative for anti-double stranded DNA antibodies in subjects with SLE. These claims highlight the potential of the method in effectively managing and improving the condition of individuals with SLE, offering new possibilities for treatment in this challenging autoimmune disease.

To know more about GlobalData’s detailed insights on UCB, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies